Latham & Watkins Represents ApiJect in US$111 Million Equity Investment by Royalty Pharma and Jefferies

ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced that it had completed a US$111 million private round of investment. The new round was led by Royalty Pharma and Jefferies Financial Group (NYSE: JEF), which acquired a revenue interest in addition to equity.

Latham & Watkins LLP represents ApiJect Holdings, Inc. in the investment round with a corporate team led by New York partner Nathan Ajiashvili and Boston partner Daniel Hoffman, with Chicago associates Jana Kovich, Kristine LaVeau, and Autumn Schmidt. Advice was also provided on benefits & compensation matters by Washington, D.C. partner David Della Rocca and Chicago associate Victoria Wolfe; on tax matters by New York partner Eric Kamerman; on antitrust matters by Washington, D.C. counsel Joseph Simei; and on CFIUS matters by Washington, D.C. partner Jim Barker.